Abraham Ronai
First SEC filing: Sept. 16, 2022 · Latest: Sept. 16, 2022
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 20, 2023 | CDNA | A | 360,000 | · | · | 515,986 Direct | +230.79% | Acquired | (price as of 2026-10-05) |
| Sept. 7, 2023 | CDNA | F | 1,465 | $8.26 | $12,101 | 155,986 Direct | -0.93% | Disposed | 745.6% (price as of 2026-10-05) |
| June 16, 2023 | CDNA | F | 3,611 | $7.96 | $28,744 | 155,199 Direct | -2.27% | Disposed | 777.5% (price as of 2026-10-05) |
| Feb. 2, 2023 | CDNA | F | 2,029 | $17.61 | $35,731 | 158,810 Direct | -1.26% | Disposed | 296.6% (price as of 2026-10-05) |
| Feb. 1, 2023 | CDNA | A | 44,100 | · | · | 44,100 Direct | · | Acquired | (price as of 2026-10-05) |
| Feb. 1, 2023 | CDNA | A | 85,100 | · | · | 160,839 Direct | +112.36% | Acquired | (price as of 2026-10-05) |
| Oct. 6, 2022 | CDNA | F | 2,492 | $18.00 | $44,856 | 75,739 Direct | -3.19% | Disposed | 288.1% (price as of 2026-10-05) |
| Oct. 6, 2022 | CDNA | F | 1,664 | $18.00 | $29,952 | 76,567 Direct | -2.13% | Disposed | 288.1% (price as of 2026-10-05) |
| Sept. 7, 2022 | CDNA | A | 12,000 | · | · | 78,231 Direct | +18.12% | Acquired | (price as of 2026-10-05) |
| Sept. 7, 2022 | CDNA | A | 36,000 | · | · | 36,000 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 1, 2023 | CDNA | Stock Option (right to buy) | Common Stock | $15.66 | Feb. 1, 2033 | 44,100 | Acquired |
| Sept. 7, 2022 | CDNA | Employee Stock Option (right to buy) | Common Stock | $18.47 | Sept. 7, 2032 | 36,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 4 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $384,844 | · | $2,190,694 | $1,936,460 | $181,643 | · | · | $4,693,641 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.